SCHEMBL2098520

SCHEMBL2098520

CCN(CC)CC(=O)Nc1cccc(OC)c1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
GAA P10253 5/20 0.60
MAPT P10636 5/20 0.60
HTT P42858 3/20 0.60
MAPK1 P28482 2/20 0.60
LMNA P02545 4/20 0.59
CYP3A4 P08684 1/20 0.51
MC4R P32245 1/20 0.51
SCN4A P35499 1/20 0.51
MC3R P41968 1/20 0.51
HTR3A P46098 1/20 0.51
SCN5A Q14524 1/20 0.51
SCN9A Q15858 1/20 0.51
SCN3A Q9NY46 1/20 0.51
BLM P54132 1/20 0.50
BRD4 O60885 1/20 0.49
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19002367 0.87 ALDH1A1 (0.76) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL2097382 0.82 ALDH1A1 (0.65) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL24499445 0.82 BRD4 (0.53) ALDH1A1KMT2AMEN1MAPTHTT
SCHEMBL22312086 0.80 BRD4 (0.53) ALDH1A1KMT2AMEN1MAPTHTT
SCHEMBL28046011 0.80 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1MAPTHTT
SCHEMBL29428945 0.80 BRD4 (0.53) ALDH1A1KMT2AMEN1MAPTHTT
SCHEMBL23222281 0.80 ALDH1A1 (0.70) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL19002363 0.77 ALDH1A1 (0.67) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL18997331 0.77 LMNA (0.69) ALDH1A1KMT2AMEN1GAAMAPT
SCHEMBL6774791 0.76 BRD4 (0.55) ALDH1A1KMT2AMEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221206-A1 Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) 2008-09-11 US claimed
US-8163803-B2 less anesthetic activity, but with more anti-inflammatory and spasmolytic activity; asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance Fundação Oswaldo Cruz—FIOCRUZ (BR) 2012-04-24 US disclosed
US-20080221206-A1 Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221206-A1 Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease LTA, LCT, LTC4S ALDH1A1 1601/4885KMT2A 3557/4885MEN1 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.